过敏与癌症。

Allergy and cancer.

作者信息

Lindelöf B, Granath F, Tengvall-Linder M, Ekbom A

机构信息

Unit of Dermatology and Venereology, Karolinska University Hospital and Institute, Stockholm, Sweden.

出版信息

Allergy. 2005 Sep;60(9):1116-20. doi: 10.1111/j.1398-9995.2005.00808.x.

DOI:10.1111/j.1398-9995.2005.00808.x

PMID:16076294

Abstract

BACKGROUND

Conflicting results have provided support for two distinct and contradictory hypotheses: (i) allergy has a protective effect against cancer by enhanced immune surveillance, and (ii) allergy is associated with an increased risk of cancer by chronic immune stimulation. We therefore aimed us to perform a large epidemiological study with a defined allergic disease cohort.

METHODS

During the years 1988-2000, 70 136 patients tested for total serum immunoglobulin E (IgE) and 57 815 tested with Phadiatop for diagnosing allergic disease at Karolinska University Hospital, Stockholm, Sweden, were linked with the Swedish Cancer Registry for a virtually complete follow up with regard to cancer.

FINDINGS

The total number of observed cancers was normal in the total serum IgE-cohort; standardized incidence ratio (SIR) = 0.98 (95% CI: 0.92-1.04) and in the Phadiatop-cohort: SIR = 0.99 (0.92-1.06) independent of the level of IgE and positive or negative Phadiatop. Specific analysis was done for cancer of the lung, cervix, pancreas, lymphoma, and nonmelanoma skin cancer. None of these forms of cancer had increased risks.

INTERPRETATION

The study does not support the hypothesis that allergy has a protective effect against cancer, nor does it support an increased risk.

摘要

背景

相互矛盾的结果支持了两种截然不同且相互矛盾的假说：（i）过敏通过增强免疫监视对癌症具有保护作用；（ii）过敏因慢性免疫刺激而与患癌风险增加相关。因此，我们旨在对一个明确的过敏性疾病队列进行大规模流行病学研究。

方法

在1988年至2000年期间，瑞典斯德哥尔摩卡罗林斯卡大学医院对70136名患者进行了血清总免疫球蛋白E（IgE）检测，对57815名患者进行了用于诊断过敏性疾病的变应原多价皮肤试验（Phadiatop）检测，并将这些患者与瑞典癌症登记处相联系，以对癌症进行几乎完整的随访。

研究结果

在血清总IgE队列中观察到的癌症总数正常；标准化发病率（SIR）=0.98（95%置信区间：0.92 - 1.04），在变应原多价皮肤试验队列中：SIR = 0.99（0.92 - 1.06），与IgE水平以及变应原多价皮肤试验阳性或阴性无关。对肺癌、宫颈癌、胰腺癌、淋巴瘤和非黑素瘤皮肤癌进行了特异性分析。这些癌症形式均未出现风险增加。